Search - tctmd.com

Displaying 121 - 140 of 205

Sort: Relevancy | Date

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

News Features

‘Outrageous’ $225,000 per Year List Price for Tafamidis Draws Outcry

Michael O'Riordan

January 10, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

News Features

Year in Review: DAPA-HF Tops Heart Failure News Amid Other Wins and Losses

December 23, 2019

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

News Features

Year in Review: SGLT2 Inhibition, Lipid-Lowering Make Waves in Clinical Cardiology in 2019

December 10, 2019

Diastolic Dysfunction Does Not Negate Health Status Benefits of TAVR

News Daily News

Diastolic Dysfunction Does Not Negate Health Status Benefits of TAVR

November 27, 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

News Conference News AHA 2019

AHA 2019: Beyond ISCHEMIA Are Plenty of Coronary, Structural, and HF Trials

November 11, 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

News Conference News HFSA 2019

New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF

September 18, 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

News Conference News ESC 2019

DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics

September 01, 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

News Conference News ESC 2019

ESC 2019: Antiplatelets in Diabetes, CAD and A-fib, an ARNI in HFpEF, Staged Complete PCI, and More

August 22, 2019

News Industry News

U.S. FDA Grants Fast Track Designation to Empagliflozin for the Treatment of Chronic Heart Failure

June 26, 2019

‘These Are Good Organs’: Drug Overdose Deaths Boost Transplants, With Few Downsides

News Daily News

‘These Are Good Organs’: Drug Overdose Deaths Boost Transplants, With Few Downsides

June 10, 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

News Conference News ESC Heart Failure 2019

Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis

May 26, 2019

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

News Daily News

Elevations in hs-cTnI Linked to Higher Risk of CVD, Particularly Heart Failure

Michael O'Riordan

May 06, 2019

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

News Daily News

Stem Cell Research—Shattered After Fabrication Scandal—Needs to Rebuild, Says EHJ Editor

Michael O'Riordan

April 12, 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

News Conference News ACC 2019

New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin

March 26, 2019

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

News Daily News

Go With NOACs Over Warfarin in Most Cases: Updated A-fib Guidelines

January 29, 2019

‘Watchful Waiting’ Tied to Poor Long-term Outcomes in Patients With Severe AR, Analysis Suggests

News Daily News

‘Watchful Waiting’ Tied to Poor Long-term Outcomes in Patients With Severe AR, Analysis Suggests

January 17, 2019

Artificial Intelligence From ECGs May ID Asymptomatic LV Dysfunction

News Daily News

Artificial Intelligence From ECGs May ID Asymptomatic LV Dysfunction

January 09, 2019

MitraClip Analysis Highlights Questions of Patient Selection in Functional MR

News Daily News

MitraClip Analysis Highlights Questions of Patient Selection in Functional MR

January 04, 2019

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

News Conference News AHA 2018

EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits

Michael O'Riordan

November 16, 2018

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.